Last updated: March 3, 2026
What is the drug identified by NDC 60687-0890?
NDC 60687-0890 corresponds to Leqembi (lecanemab), an amyloid-beta antibody developed by Eisai and Biogen. It was approved by the FDA on January 6, 2023, for the treatment of Alzheimer's disease in patients with early-stage disease.
Market Overview
Demand Drivers
- Increasing prevalence of Alzheimer's disease: Over 6 million Americans, projected to rise to 13.8 million by 2050 (Alzheimer's Association, 2022).
- Unmet clinical need: Limited effective disease-modifying treatments.
- FDA approval specifics: Accelerated approval pathway based on biomarker reduction; ongoing trials to confirm clinical benefit.
Competitive Landscape
- Main competitors include Biogen's Aduhelm (aducanumab), developed under the same amyloid-targeting paradigm.
- Aduhelm launched in 2021 at a list price of approximately $56,000 annually.
- Other emerging therapies: Donanemab by Lilly, Lecanemab provides a potentially superior efficacy profile.
Market Penetration Factors
- Patient eligibility criteria: Early-stage Alzheimer's, confirmed via PET scans or CSF biomarkers.
- Reimbursement landscape: CMS coverage policies are evolving; initial broad coverage followed by potential restrictions.
- Physician acceptance: Gradual, influenced by safety profile concerns and clinical trial data.
Price Trajectory Analysis
Current Pricing
- List Price Approximate: $26,500 per year, based on Eisai's published pricing (Eisai, 2023).
- Insurance Coverage: Coverage policies are still adapting; out-of-pocket varies.
Price Trends and Projections
| Year |
Estimated Price Range |
Key Factors |
| 2023 |
$26,500 |
Launch price, initial coverage decisions, manufacturer discounts |
| 2024 |
$24,000 - $28,000 |
Competition, payer negotiations, volume discounts |
| 2025 |
$22,000 - $26,000 |
Increased competition, biosimilar potential, payer pressure |
| 2030 |
$18,000 - $24,000 |
Broader adoption, biosimilar entries, manufacturing efficiencies |
Market Factors Influencing Price Movement
- Payer negotiating power: Will drive discounts; large insurers may push for lower prices.
- Biosimilar entry: Regulatory pathway for biosimilar lecanemab may develop by late 2020s, exerting downward pressure.
- Manufacturing costs: Potential declines as production scales, impacting retail price.
Cost-Effectiveness Considerations
- Cost per Quality-Adjusted Life Year (QALY) estimates vary from $150,000 to $300,000 depending on assumptions.
- Value-based pricing models may emerge as more data on long-term efficacy becomes available.
Revenue Projections
Based on conservative market penetration assumptions:
- Year 1 (2023): 100,000 patients at $26,500, generating approximately $2.65 billion.
- Year 5 (2027): Potential 500,000 patients, assuming 30% penetration, yielding ~$13.4 billion.
Market Share Outlook
- Leqembi's market share expected to grow as clinical confidence and reimbursement improve.
- Early adoption likely prioritized by specialists; broader primary care distribution possible over time.
Regulatory and Policy Impact
- Ongoing surveillance for adverse effects such as amyloid-related imaging abnormalities (ARIA).
- CMS adjustments could impact pricing and patient access.
- Expansion to other indications (e.g., different stages) could influence volume and price.
Key Challenges
- Safety concerns: ARIA risks impact prescribing.
- Reimbursement hurdles: Payer restrictions may limit market growth.
- Competition: Biosimilars and new therapeutics may reduce price and market share.
Summary
Leqembi is positioned as a leading treatment for early Alzheimer's. Its initial price of approximately $26,500 aligns with similar therapies but is subject to downward pressure from competition, biosimilar development, and payer negotiations. Revenue could approach $13 billion annually within five years, with prices declining to reflect market dynamics and clinical experience.
Key Takeaways
- Leqembi's initial annual price is around $26,500.
- Market growth hinges on clinical uptake, reimbursement, and safety profile management.
- Price projections suggest a gradual decline, potentially reaching $18,000–$24,000 by 2030.
- Competitive pressures and biosimilars are critical factors influencing price movements.
- Long-term revenue could surpass $13 billion annually with widespread adoption.
FAQs
-
What factors most influence drug pricing in this context? Reimbursement policies, competition, manufacturing costs, clinical efficacy, and safety profile.
-
How does Leqembi compare to Aduhelm in pricing? Leqembi's list price is lower, approximately $26,500 versus Aduhelm’s $56,000 per year, but market penetration is still evolving.
-
What is the potential impact of biosimilars? Biosimilars could reduce prices by up to 30-50%, depending on regulatory approval and market acceptance.
-
Are there upcoming regulatory decisions that could affect pricing? Yes, approvals for expanded indications or biosimilar pathways could significantly influence market dynamics.
-
How will reimbursement policies shape market access? Payers are likely to impose restrictions until efficacy and safety data are well-established, influencing uptake and pricing flexibility.
References
[1] Alzheimer's Association. (2022). 2022 Alzheimer's Disease Facts and Figures. Alzheimer’s & Dementia, 18(4), 700-789.
[2] Eisai. (2023). Leqembi (lecanemab) Pricing and Availability. Retrieved from https://www.eisai.com
[3] U.S. Food & Drug Administration. (2023). FDA approves Leqembi (lecanemab) to treat Alzheimer’s disease. https://www.fda.gov/news-events/press-announcements
[4] MarketWatch. (2023). Alzheimer drug market forecast and competition analysis. Retrieved from https://www.marketwatch.com
